MAPK8 and neoplasm: High-risk group patients have been found to exhibit higher IC50 levels to pathway inhibitors such as AKT inhibitors, JNK inhibitors, and some drugs approved for anti-tumor treatment, such as Pazopanib, Lapatinib, Crizotinib, among others.